SDC-1801

SDC-1801 is a small molecule, orally administered dual inhibitor of tyrosine kinase 2 (TYK2) and Janus kinase 1 (JAK1), both members of the JAK family of proteins. It is being developed by Sareum as a potential treatment for a range of autoimmune diseases, with an initial focus on psoriasis. The drug acts by inhibiting TYK2 and JAK1 signaling pathways, which are implicated in the pathogenesis of several immune-mediated disorders. Preclinical and early clinical studies have demonstrated that SDC-1801 has a favorable safety profile, with no serious adverse events reported in Phase 1 trials. The compound has shown potential for once-daily oral dosing due to its pharmacokinetic properties[2][4][5][6][9].